Diagnosis and Pathology: Biopsies and Angiography

Confirming a diagnosis of Polyarteritis nodosa (PAN) is often a process of “connecting the dots” because there is no single blood test that can definitively say you have the disease ^[1][2]. Instead, doctors rely on a combination of your symptoms, detailed imaging of your blood vessels, and microscopic examination of your tissues ^[2][3].

The Role of Tissue Biopsy

A biopsy—taking a small sample of tissue from an affected area like the skin, a nerve, or a muscle—is often considered the most reliable way to confirm PAN ^[2]. Under a microscope, a pathologist looks for very specific signs of damage in the medium-sized arteries:

• Necrotizing Arteritis: This is severe inflammation that actually destroys the layers of the artery wall ^[4].
• Fibrinoid Necrosis: This is a hallmark finding where a protein called fibrin builds up in the damaged vessel wall, creating a “scar-like” appearance that signals the death of vessel tissue ^[4][5].
• Neutrophil Infiltration: Doctors look for an abundance of neutrophils (a type of white blood cell) swarming the area, which indicates an active, aggressive immune attack on the blood vessel ^[4][6].

Imaging: Looking for the “String of Beads”

If a biopsy is too risky or if the affected organs are deep inside your body, doctors use angiography (a specialized X-ray or CT scan of the blood vessels) ^[7]. They are searching for vascular irregularities in the arteries supplying the kidneys, liver, or gut ^[8][9]:

• Microaneurysms: These are tiny, balloon-like bulges in the weakened artery walls ^[10].
• Beading: This is a classic pattern where the artery shows alternating areas of narrowing (stenosis) and bulging. This creates an appearance often described by radiologists as a “string of beads” ^[8][11].

Why “Old Rules” No Longer Apply

You may come across the 1990 ACR (American College of Rheumatology) classification criteria for PAN. While these were groundbreaking at the time, modern rheumatologists now view them as outdated and potentially misleading ^[12][13].

The main reason for this shift is the discovery of ANCA (Anti-Neutrophil Cytoplasmic Antibodies) ^[14]. In 1990, doctors didn’t have a routine test for these antibodies. As a result, many patients who were diagnosed with PAN back then actually had Microscopic Polyangiitis (MPA), a different disease that is ANCA-positive and affects much smaller blood vessels ^[13][12].

Today, a modern diagnosis requires the absence of ANCA and the absence of glomerulonephritis (a specific type of kidney inflammation common in MPA but rare in PAN) ^[14][1]. Distinguishing between the two is critical because the treatments and long-term outlook for each condition are different. Diagnosis now focuses on these more precise, updated distinctions to ensure you receive the most targeted care possible ^[1].